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 26 
Abstract 27 
Background: Oesophageal candidiasis is a common, usually self-limiting opportunistic infection, 28 
but long-term infection with Candida is known to predispose to squamous cell oral and oesophageal 29 
cancer (SSC). Permissive factors that lead to immune deficiencies can underlie persistent or 30 
recurring candidiasis, called chronic mucocutaneous candidiasis (CMC). Secondary immune 31 
deficiencies are most often due to Human Immunodeficiency virus (HIV) infection, antibiotic use 32 
and immunosuppressive treatment (steroids, chemotherapy). Inborn errors of the immune system 33 
(primary immune deficiencies- PID) can present with isolated CMC known as CMC disease 34 
(CMCD), which is most often found in patients with autoimmune poly-endocrinopathy type 1 35 
APS1/APECED or in patients with an underlying gain-of-function STAT1 mutation (GOF-STAT1). 36 
Objective: To describe a new form of inherited/familial chronic mucocutaneous candidiasis with a 37 
high risk for developing squamous cell carcinoma of the oesophagus, due to a gain-of-function 38 
mutation in the STAT1 gene.   39 
Methods and results: This report describes a family of patients with CMC with confirmed GOF 40 
STAT1 mutation. These patients usually present with CMCD  in childhood, have severe oral and 41 
oesophageal candidiasis accompanied by severe difficulty swallowing, chest pain, heartburn, and 42 
are at risk of developing oral and/or oesophageal SSC. This case series describes 6 5 patients in 3 43 
generations of the same family, 2 of whom developed and died of SSC. We recommend regular 44 
endoscopic surveillance to detect early oesophageal neoplasia in patients with CMCD as well as 45 
urgent endoscopy in symptomatic patients. 46 
Conclusion: CMC is not a well recognised condition in gastroenterology practice and clinicians 47 
need to be aware of the genetics of the condition as well as the risk for oesophageal cancer so that 48 
they can counsel their patients and arrange surveillance appropriately. 49 
Word count: 274 50 
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 58 
Study Highlights 59 
1. What is the current knowledge? 60 
a. CMC is not very well recognised amongst Gastroenterologists in patients with 61 
persistent and recurrent oral or cutaneous candidiasis 62 
b. CMC can be due to secondary immune deficiencies such as type 1 APS1/APECED  63 
 64 
2. What is new here? 65 
a. CMC can be due to Gain-of-function STAT1 mutations. 66 
b. CMC can cause oesophageal squamous cell cancer in younger patients 67 
c. Symptomatic patients with CMC should be gastroscoped urgently rather than treated 68 
with trial of proton pump inhibitor despite their young age 69 
d. Surveillance endoscopy with advanced imaging is recommended for all patients with 70 
CMC and a GOF-STAT1 mutation 71 
 72 
 73 
 74 
 75 
 76 
 77 
 78 
  79 
4 
 
Introduction 80 
Candida is an opportunistic yeast, colonising gastrointestinal and urogenital mucosa in 81 
about 30–50% of healthy humans without causing infection. Candida overgrowth requires 82 
permissive circumstances which occur when the immune system is damaged, leading to either 83 
primary or secondary immune deficiencies, which, depending on the underlying immune defect, 84 
will lead to infections of the skin, nails and mucosa (oral, oesophageal, genital) with Candida, 85 
coined chronic mucocutaneous candidiasis (CMC), or to invasive disease (sepsis) with internal 86 
organ involvement. Secondary CMC can be precipitated by a range of factors, the most common 87 
being secondary immune deficiency caused by Human Immunodeficiency Virus (HIV) infection, 88 
when CD4 T lymphocyte counts fall to < 100 cells/μL, precipitating Acquired Immune Deficiency 89 
Syndrome (AIDS). Other frequent precipitating factors include use of antibiotics and 90 
immunosuppressive drugs such as long-term systemic or inhaled corticosteroids, chemotherapy for 91 
malignancies, as well as other diseases such as diabetes or local factors such as dentures (1). 92 
In contrast to the above, in patients with inborn (genetic) errors of the immune system 93 
known as primary immune deficiencies (PIDs), CMC can present as a syndrome with chronic, 94 
persistent or recurrent, debilitating Candida infection of the skin, nails and mucous membranes 95 
without an obvious cause as defined above. (Figures 2, 3) In these patients, CMC, especially oral 96 
Candida infection (thrush) may occur either in isolation (CMC disease – CMCD), as part of well-97 
defined PID syndromes or part of a broad, severe immune deficiency. Patients with the autosomal 98 
dominant (AD) hyper IgE syndrome (HIES) suffer with CMC as well as severe skin and pulmonary 99 
staphylococcal infections. This is caused by a mutation in the Signal transducer and activator of 100 
transcription 3 (STAT3) gene resulting in a faulty STAT3 function, leading to significantly reduced 101 
levels of CD4 T helper (Th)-17 cells and circulating interleukin (IL)-17 and IL-22 cytokines. CMC 102 
can also be part of a complex clinical phenotype caused by severe immune deficiencies affecting T 103 
lymphocytes, where patients suffer with susceptibility to a broad range of microorganisms rather 104 
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than selective fungal infections. Accumulating evidence suggests that mucocutaneous fungal 105 
infections accompany a variety of defects that disrupt the Th-17 pathway (2) while protection 106 
against invasive disease is mediated by phagocytes, and indeed CMC patients rarely if ever develop 107 
invasive fungal disease (1).  108 
Oesophageal candidiasis can present as dysphagia, odynophagia, retrosternal chest pain, or 109 
can be an incidental finding at endoscopy. Its typical endoscopic appearance is of white plaques 110 
which persist despite water flushes. Oesophageal brushings and biopsy show the characteristic 111 
appearance of yeasts and pseudo hyphae. The most common organism associated with this is 112 
Candida albicans, although other strains such as C. glabarata and C. tropicalis are increasingly 113 
being isolated.  Common endoscopic findings associated with oesophageal candidiasis include 114 
oesophageal ulcer, gastric ulcer and severe atrophic gastritis (3). Rare complications include 115 
ulceration, haemorrhage or oesophageal obstruction from stricture or fistulation to bronchial tree (4). 116 
For most patients one course of antifungal treatment is sufficient to resolve the problem, and repeat 117 
gastroscopy is very rarely needed. 118 
 In rare patients with an underlying PID, the oesophageal candidiasis presents as CMCD 119 
with recurrent or persistent thrush despite multiple courses of antifungal treatment; it is usually 120 
accompanied by candidiasis of the skin, nails and other mucous membranes, and often presents in 121 
early childhood and frequently involves multiple family members.  122 
CMCD is known to be caused by at least 5 different mutations affecting the IL-17 pathways 123 
(2), but the 2 most common causes of CMCD are Autoimmune Polyendocrinopathy Candidiasis 124 
Ectodermal Dystrophy (APECED), also known as Autoimmune Polyendocrinopathy type 1 (APS1) 125 
and autosomal dominant (AD) gain-of-function (GOF) gene mutation of the signalling protein 126 
STAT1 (Signal Transducer and Activator of Transcription 1).   127 
In APECED/APS1, CMC is seen in >95% of patients, often as the first presenting symptom 128 
of disease, followed by the development of a triad of hypoparathyroidism, adrenal and gonadal 129 
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failure, as well as other endocrine organ involvement (e.g. diabetes). APECED is caused by an 130 
inborn error (mutation) of the AIRE gene, inherited in an autosomal recessive manner. AIRE is a 131 
transcription factor that promotes the ectopic presentation of self-antigens in the thymic medulla, 132 
ensuring removal of self-reactive T lymphocytes in the process of thymic T cell maturation. 133 
Defective AIRE function and failed removal of auto-reactive T cells results in autoimmunity, 134 
causing endocrine organ failure; however, why these patients develop CMC was a mystery until we 135 
(5) and others (6) demonstrated in APECED/APS1 patients the production of neutralizing 136 
autoantibodies to Th-17 cytokines IL-17A-F and IL-22, disrupting Th-17 mediated fungal immunity, 137 
which explained why these patients develop CMC in the context of the underlying autoimmunity.  138 
In the other largest group of patients with CMCD, we and others recently identified a gain-139 
of-function (GOF) mutation in the STAT1 gene as the underlying cause (7, 8). Although the 140 
pathogenic mechanisms are still not fully understood, it is thought that the genetic defect results in 141 
exaggerated Th1 responses which down regulate STAT3/Th17 immunity, leading to reduced 142 
production of IL-17 and IL-22 (9).  In these patients, there have been sporadic reports of a link 143 
between CMC and oesophageal squamous cell carcinoma (10) confirmed in a recent international 144 
review of these rare patients (11) In view of the increasingly recognised association of SCC and 145 
GOF-STAT1-CMC, we present a case series in a family of 3 generations with this disease. (Figure 146 
1). 147 
 148 
 149 
 150 
 151 
 152 
 153 
 154 
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Case series  155 
Our index patient (patient (pt) 1) was a mother of 5 children. She suffered since childhood 156 
with severe CMCD presenting as oral, oesophageal and genital candidiasis and multiple, severe nail 157 
involvement as well as gastric reflux and difficulty swallowing, hypothyroidism, keratitis, 158 
blepharitis, conjunctivitis, styes, eczema, skin abscesses/boils and dental loss. At 58 years of age, 159 
she developed oral squamous cell cancer (SCC) which was treated with surgery and radiotherapy 160 
but lead to her death 3 years later. 161 
Of her 5 children, 3 had CMCD. The eldest was a son (pt 2), who presented in childhood 162 
with severe CMCD, recurring lung disease with bronchiectasis, chronic obstructive pulmonary 163 
disease (COPD) and widespread eczema, skin infections, abscesses and boils. As an adult, he had 164 
intermittent oral thrush which was treated with anti-fungals (Figure 2). He also suffered with 165 
indigestion, dysphagia and odynophagia which responded well to proton pump inhibitors. At the 166 
age of 40 he had a gastroscopy for persistent symptoms which revealed marked oesophageal 167 
candidiasis as well as widespread oesophageal squamous cell carcinoma. Immunosuppressive 168 
chemotherapy was avoided in view of his underlying PID and instead he received palliative 169 
radiotherapy for extensive bony metastases, but passed away 6 months after diagnosis. The second 170 
sibling was his sister (pt 3) aged 34, who presented with chronic oral thrush since childhood which 171 
was treated with daily antifungals but nevertheless went on to developed severe dysphagia. 172 
Gastroscopy revealed stricturing of the oesophagus and the procedure was abandoned due to poor 173 
tolerance. She declined further investigations or surveillance. The third sibling (pt 4), who also had 174 
CMCD since childhood, was a younger brother aged 32, with intermittent oral thrush who 175 
underwent an initial gastroscopy at 25 years old, which revealed erosive oesophagitis. A repeat 176 
surveillance gastroscopy 7 years later was normal, with oesophageal biopsies showing mild 177 
oesophagitis with no dysplasia or candidiasis.  178 
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In the third generation, of the 3 children of the eldest brother, 2 have inherited this mutation and 179 
illness. The eldest daughter (pt 5), aged 21 has severe CMCD, bronchiectasis, and suffers with 180 
severe dysphagia, heartburn and chest pain. Although the initial gastroscopy was normal, a repeat 181 
endoscopy a year later for progressive symptoms although macroscopically normal revealed the 182 
presence of chronic inflammation without dysplasia at histology. The younger daughter (pt 6) aged 183 
12 years, developed oral candidiasis aged 3, which perseveres intermittently. Clinical findings 184 
including other infections and autoimmune features are presented in Table 1. Immunological work-185 
up for these patients is summarized in Table 2 which demonstrates that routine immunological 186 
findings are generally normal. However, specialized tests assessing STAT1 function by measuring 187 
STAT1 activity following stimulation with interferons either by assessing phosphorylated STAT1 188 
(pSTAT1) using flow-cytometry or by measuring STAT1-dependent gene transcription using 189 
quantitative real-time polymerase chain reaction (qRT-PCR) (described in 9) confirmed STAT1 190 
hyperactivity. For patients 1-5 this was previously reported (12) while findings for pt 6 are shown in 191 
Fig 4. All our patients had a heterozygous A267V mutation (c.800C>T  p.Ala267Val) in the coiled-192 
coiled (CC) domain of the STAT1 gene. Patients 1-4 were the first patients in whom this GOF-193 
STAT1 mutation was found by targeted sequencing and reported (7). The remaining 2 family 194 
members (patients 5 and 6) were tested as part of their clinical work-up in view of their specific 195 
family history. 196 
 197 
Discussion 198 
It is now recognised that patients with CMCD, particularly those with the GOF-STAT1 199 
mutation have a broad clinical phenotype, significantly reduced life expectancy and an increased 200 
incidence of SSC (11). Management of these patients always includes antifungal therapy to control 201 
mucocutaneous cutaneous candidiasis in spite of which SCC develops, indicating the need to 202 
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consider urgent gastroscopies in the symptomatic patient as well as regular annual surveillance 203 
endoscopy with Lugol’s iodine chromoendoscopy to detect squamous dysplasia.  204 
Unlike conventional oesophageal carcinoma, patients who develop oesophageal SCC on a 205 
background of CMCD present at a younger age. Delsing et al reported a 25-year-old female who 206 
presented with dysphagia on a background of CMCD and GOF-STAT1 gene mutation, where the 207 
initial gastroscopy revealed only candidiasis, but the cytology confirmed malignant epithelial cells. 208 
A repeat gastroscopy 2 weeks later identified an irregular stenosis at 26cm, and its histology was in 209 
keeping with SCC. Due to limited disease, the patient went on to have an oesophagectomy with 210 
reconstruction and colonic interposition with no further recurrence of oesophageal candidiasis nor 211 
malignancy 20 years later (10).   212 
The pathogenic mechanisms leading to SCC in the presence of CMCD are not fully 213 
understood, but it is believed to be due to chronic inflammation caused by the infection, as well to 214 
candidial catalytic activity leading to the production of nitrosamines such as nitroso-N-215 
methylbenzylamine (NBMA) which is carcinogenic (12 13).  216 
It is well known that the STAT1 gene is integral to innate immunity and mediates signalling 217 
of important inflammatory cytokines such as interferons (IFN) gamma (γ) and alpha (α). STAT1 is 218 
involved in mediating antibacterial, antiviral and antifungal immune responses, suppression of cell 219 
growth, and apoptosis as well as tumour genesis and tumour suppression (13 14). Some reports 220 
have found its levels to be reduced in transformed cancer cells, suggesting tumour suppressor 221 
properties, which is also supported by Zhang et al who found that transfection of STAT1c into 222 
oesophageal squamous cell carcinoma cells resulted in apoptosis and cell cycle arrest, while the 223 
absence of STAT 1 was associated with poorer outcomes (14 15).  224 
Due to the high risk of oesophageal SCC in patients with CMCD, these patients should have 225 
an endoscopy if they have any upper gastrointestinal symptoms. They should also have regular 226 
surveillance endoscopy with chromoendoscopy using Lugol’s iodine or narrow band imaging to 227 
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detect squamous dysplasia or early cancers. These patients present at a younger age compared to the 228 
conventional age for presentation of sporadic oesophageal squamous cell cancer. Although the age 229 
at which this surveillance should start is not clear, it should be at least a decade earlier than the age 230 
of youngest member of the family diagnosed with oesophageal cancer. The intervals for 231 
surveillance endoscopy are also not certain, but at least annually or biannually. Squamous dysplasia 232 
of the oesophagus can now be treated endoscopically by endosocopic resection and radiofrequency 233 
ablation (15 16).  234 
In view of the fact that the underlying mutation has been identified as a GOF-STAT1, new 235 
therapeutic approaches should also be considered such as inhibition of STAT1 signalling by 236 
specific inhibitors of the JAK-STAT signalling pathway. Obviously, the potential deleterious 237 
effects of inhibiting a crucial inflammatory pathway must be weighed against potential benefits, but 238 
it is encouraging to know that sporadic case reports have reported significant benefits without major 239 
side-effects (17). However, this area still requires significant research.  240 
 241 
Conclusion 242 
In patients who present with recurrent oesophageal candidiasis we advise taking a thorough 243 
history, focusing on elements suggesting a PID such as age of onset, involvement of other body 244 
areas (skin and nail candidiasis), other infections, past medical history and family history of 245 
candidiasis. Additional testing should always exclude HIV infection as a cause of secondary 246 
immune deficiency. Consultation and/or referral to Clinical Immunology colleagues for further 247 
investigation and subsequent management of underlying PID is indicated.  248 
CMC has a strong association with oral and oesophageal SCC, as such, these patients should 249 
be routinely monitored and investigated urgently if they present with upper gastrointestinal 250 
symptoms to detect early oesophageal cancer.  251 
  252 
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Figure legends: 298 
Figure 1. Family tree of CMC patients Anjan: this needs correcting as the 6th patient is not 299 
mentioned in the figure; I have added her in the text (pp8, line 186-7) 300 
Figure 2. Appearance of the nails in CMC 301 
Figure 3. Appearance of the tongue in CMC 302 
Figure 4.  303 
STAT1 gain-of function in CMC patient 5. A) STAT1 phosphorylation following stimulation 304 
with interferon (IFN) was assessed by flowcytometry. Whole blood from a healthy control and 305 
CMC patient 5 was stimulated with 103 IU/ml interferon (IFN)α (IFN-α2b IntronA, Merck Sharp & 306 
Dohme) for 30 minutes, cells were fixed, permeablized and stained with Alexa Fluor R 647 STAT1 307 
(pY701) for pSTAT1 and CD3 Pacific Blue antibody for CD3+ T cells (all reagents from BD). Data 308 
were collected with a FACSCaliber (BD) and analysed with FlowJo software. Grey = healthy 309 
control; black = CMC patient; clear peaks = unstimulated cells; full peaks = IFNα stimulated cells. 310 
Median fluorescence intensity (MFI) is shown. B. qRT-PCR of STAT1-dependent gene 311 
expression for CXCL10 and IRF1. In a healthy control and CMC patient 5, peripheral blood 312 
mononuclear cells were isolated and cultured in RPMI medium for 4 h with 1 × 103 IU/ml IFNα 313 
(IFN-α2b IntronA, Merck Sharp & Dohme), 1 μg/ml IFNγ (R&D Systems). Total RNA was 314 
purified using RNeasy Mini Kit (Qiagen) and reverse-transcribed into cDNA. Gene expression 315 
analysis for CXCL1o and IRF1 mRNA was performed with custom TaqMan gene expression 316 
assays (ABI). Gene expression was normalized to the housekeeping gene 18S rRNA. Data is 317 
expressed in the 2−Ct format, where Ct = Ct (target) – Ct (18S). Results are for n=3 replicates. 318 
Statistical significance was assessed by unpaired, two-tailed t test using Prism software.* = p>0.05; 319 
** = p>0.01 320 
 321 




  
Table 1. Clinical findings in CMC patients with GOF-STAT1 mutation A267V 
 Pt 1 Pt 2 Pt 3 Pt 4 Pt 5 Pt 6 
Age / Gender 58/F 40/M 34/F 32/M 21/F 12/F 
Candida Infections 
Oral + + + + ++ ++ 
Genital - - - + - - 
Nails + ++ + + + + - 
Other Infections 
Skin 
(abscesses/boils) + +++ + + - - 
Eczema ++ ++ + +++ - - 
Lungs 
Bronchiectasis/COPD - ++ - - +++ - 
Autoimmunity       
Hypothyroidism ++ - - + - - 
Ocular 
Keratitis + - +++ + - - 
Conjunctivitis ++ ++ + + - - 
Other findings       
Dental loss ++ +++ - - - - 
Reflux/diff swallowing ++ ++ +++ +++ +++ - 
Oral/Oesoph Ca + + - - - - 
Pt = patient; F = female; M = male 
 
  
 
Table 2. Immunological findings in CMC patients with GOF-STAT1 mutation A267V 
 Pt 1 Pt 2 Pt 3 Pt 4 Pt 5 Pt 6 Normal 
ranges Age / Gender 58/F 40/M 34/F 32/M 21/F 12/F 
Immunoglobulins (g/L)  
IgG 19.6 11.1 11.9 11.4 11.0 9.0 5.8-15.4 
IgA 3.21 ↑ 1.46 4.14 ↑ 4.12 ↑ 2.91 1.24 0.64-2.97 
IgM 3.62 ↑ 1.54 1.71 0.98 1.38 1.17 0.71-2.30 
IgG subclasses 1-4 normal normal normal normal normal normal  
C3/C4 complement normal normal normal normal normal normal  
HIB abs >9.0 6.5 0.4 ↓ 1.5 >9 >9 1-20mg/L 
Pneumococcal abs 241 171 67 50 125 52 20-200mg/L 
Lymphocyte subsets (cells/ul)  
CD3+ T cells 1751 1064 1268 1496 1393 1946 690-2540 
CD4+ T cells 1127 690 955 874 701 879 410-1590 
CD8+ T cells 521 304 250 513 597 859 190-1140 
CD4/CD8 ratio 2.16 2.26 3.82 ↑ 1.70 1.17 1.02 1.0-3.6 
CD19+ B cells 307 362 348 392 144 709 90-660 
CD 56+ NK cells 156 84 62 146 91 172 90-590 
Lymphocyte proliferation  
Mitogen PHA normal normal normal normal normal normal  
Candida albicans normal normal normal normal normal normal  
Other  
Thyroid function hypoth normal hypothy normal normal normal  
Thyroid abs (TPO) >1300 ↑ 74 ↑  55 162 ↑  50 8 0-59ku/L 
Antinuclear abs negative negative negative negative negative negative  
Pt = patient; F = female; M = male; abs = antibodies; PHA = phytohaemagglutinin; TPO = thyroid peroxidase 
